

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
 US Department of Commerce  
 United States Patent and Trademark  
 Office, PCT  
 2011 South Clark Place Room  
 CP2/5C24  
 Arlington, VA 22202  
 ETATS-UNIS D'AMERIQUE  
 in its capacity as elected Office

<b>Date of mailing</b> (day/month/year) 13 July 2001 (13.07.01)	
<b>International application No.</b> PCT/EP00/09149	<b>Applicant's or agent's file reference</b> 0480/001219
<b>International filing date</b> (day/month/year) 19 September 2000 (19.09.00)	<b>Priority date</b> (day/month/year) 24 September 1999 (24.09.99)
<b>Applicant</b> HANTKE, Thomas et al	

1. The designated Office is hereby notified of its election made:



in the demand filed with the International Preliminary Examining Authority on:

23 April 2001 (23.04.01)



in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<b>The International Bureau of WIPO</b> 34, chemin des Colombettes 1211 Geneva 20, Switzerland  Facsimile No.: (41-22) 740.14.35	<b>Authorized officer</b>  A. Karkachi  Telephone No.: (41-22) 338.83.38
--	--



## PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING  
OF A CHANGE(PCT Rule 92bis.1 and  
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

KINZEBACH, Werner  
Ludwigsplatz 4  
67059 Ludwigshafen  
ALLEMAGNE

Date of mailing (day/month/year) 13 July 2001 (13.07.01)	<b>IMPORTANT NOTIFICATION</b>
Applicant's or agent's file reference 0480/001219	
International application No. PCT/EP00/09149	International filing date (day/month/year) 19 September 2000 (19.09.00)

## 1. The following indications appeared on record concerning:

☐ the applicant      ☐ the inventor      ☒ the agent      ☐ the common representative

## Name and Address

GOLDSCHIED, Bettina  
BASF Aktiengesellschaft  
67056 Ludwigshafen  
Germany

State of Nationality

State of Residence

Telephone No.

0621/60-78916

Facsimile No.

0621/60-43123

Teleprinter No.

## 2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person      ☐ the name      ☒ the address      ☐ the nationality      ☐ the residence

## Name and Address

KINZEBACH, Werner  
Ludwigsplatz 4  
67059 Ludwigshafen  
Germany

State of Nationality

State of Residence

Telephone No.

0621/591390

Facsimile No.

0621/628441

Teleprinter No.

## 3. Further observations, if necessary:

## 4. A copy of this notification has been sent to:

<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned
<input checked="" type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:

<b>The International Bureau of WIPO</b> 34, chemin des Colombettes 1211 Geneva 20, Switzerland  Facsimile No.: (41-22) 740.14.35	Authorized officer  A. Karkachi  Telephone No.: (41-22) 338.83.38
--	---



## PATENT COOPERATION TREATY

PCT

From the INTERNATIONAL BUREAU

NOTIFICATION OF THE RECORDING  
OF A CHANGE(PCT Rule 92bis.1 and  
Administrative Instructions, Section 422)

To:

KINZEBACH, Werner  
Ludwigsplatz 4  
67059 Ludwigshafen  
ALLEMAGNE

Date of mailing (day/month/year) 11 April 2002 (11.04.02)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference M42109-PCT	
International application No. PCT/EP00/09149	International filing date (day/month/year) 19 September 2000 (19.09.00)

## 1. The following indications appeared on record concerning:

☒ the applicant
 ☐ the inventor
 ☐ the agent
 ☐ the common representative

Name and Address KNOLL AKTIENGESELLSCHAFT 67061 Ludwigshafen Germany	State of Nationality DE	State of Residence DE
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

## 2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person
 ☒ the name
 ☒ the address
 ☐ the nationality
 ☐ the residence

Name and Address ABBOTT GMBH & CO. KG Max-Planck-Ring 2 D-65205 Wiesbaden Germany	State of Nationality DE	State of Residence DE
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

## 3. Further observations, if necessary:

## 4. A copy of this notification has been sent to:

<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned
<input type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Lazar Joseph PANAKAL Telephone No.: (41-22) 338.83.38
---	--



## PATENT COOPERATION TREATY

PCT

From the INTERNATIONAL BUREAU

NOTIFICATION OF THE RECORDING  
OF A CHANGE(PCT Rule 92bis.1 and  
Administrative Instructions, Section 422)

To:

KINZEBACH, Werner  
Ludwigsplatz 4  
67059 Ludwigshafen  
ALLEMAGNE

<b>Date of mailing</b> (day/month/year) 10 April 2002 (10.04.02)	<b>IMPORTANT NOTIFICATION</b>
<b>Applicant's or agent's file reference</b> 0480/001219	
<b>International application No.</b> PCT/EP00/09149	<b>International filing date</b> (day/month/year) 19 September 2000 (19.09.00)

<b>1. The following indications appeared on record concerning:</b> <input checked="" type="checkbox"/> the applicant <input type="checkbox"/> the inventor <input type="checkbox"/> the agent <input type="checkbox"/> the common representative		
<b>Name and Address</b> KNOLL AKTIENGESELLSCHAFT 67061 Ludwigshafen Germany	<b>State of Nationality</b> DE	<b>State of Residence</b> DE
	<b>Telephone No.</b>	
	<b>Facsimile No.</b>	
	<b>Teleprinter No.</b>	
<b>2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:</b> <input type="checkbox"/> the person <input checked="" type="checkbox"/> the name <input checked="" type="checkbox"/> the address <input type="checkbox"/> the nationality <input type="checkbox"/> the residence		
<b>Name and Address</b> ABBOTT GmbH & Co. KG Max-Planck-Ring 2 D-65205 Wiesbaden Germany	<b>State of Nationality</b> DE	<b>State of Residence</b> DE
	<b>Telephone No.</b>	
	<b>Facsimile No.</b>	
	<b>Teleprinter No.</b>	
<b>3. Further observations, if necessary:</b>  		
<b>4. A copy of this notification has been sent to:</b> <input checked="" type="checkbox"/> the receiving Office <input type="checkbox"/> the designated Offices concerned <input type="checkbox"/> the International Searching Authority <input checked="" type="checkbox"/> the elected Offices concerned <input type="checkbox"/> the International Preliminary Examining Authority <input type="checkbox"/> other:		

<b>The International Bureau of WIPO</b> 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	<b>Authorized officer</b> Lazar Joseph PANAKAL Telephone No.: (41-22) 338.83.38
--	---






# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 0480/001219		<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/EP00/09149	International filing date (day/month/year) 19/09/2000	Priority date (day/month/year) 24/09/1999	
International Patent Classification (IPC) or national classification and IPC C07D239/48			
Applicant KNOLL AKTIENGESELLSCHAFT et al.			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 5 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 1 sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li>I <input checked="" type="checkbox"/> Basis of the report</li> <li>II <input type="checkbox"/> Priority</li> <li>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li> <li>IV <input type="checkbox"/> Lack of unity of invention</li> <li>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li>VI <input checked="" type="checkbox"/> Certain documents cited</li> <li>VII <input checked="" type="checkbox"/> Certain defects in the international application</li> <li>VIII <input type="checkbox"/> Certain observations on the international application</li> </ul>			
Date of submission of the demand 23/04/2001		Date of completion of this report 11.12.2001	
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Authorized officer  Beeck, M  Telephone No. +49 89 2399 8473	





# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/09149

## I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, pages:**

1-15 as originally filed

**Claims, No.:**

1 (part), 6-15 as originally filed

1 (part), 2-5 as received on 21/11/2001 with letter of 21/11/2001

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/09149

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

## V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

### 1. Statement

Novelty (N)	Yes:	Claims	1-15
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-15
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-15
	No:	Claims	

2. Citations and explanations  
**see separate sheet**

## VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

**see separate sheet**

## VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:  
**see separate sheet**



**SECTION V:**

- 1) The documents are numbered according to their sequence in the search report.
- 2) Document D5 discloses in example 39, column 37, (b) Tablet II, a tablet comprising a 4,6-dianilino-pyrimidine derivative of formula (I), falling under the general formula of present claim 1, and polyvinylpyrrolidone.

Documents D6 and D7 describe substituted 2-anilinopyrimidines, falling under the general formula of present claim 1, with polyvinylpyrrolidone as binding agent (see D6, page 15, line 17, and D7, page 17, line 11).

Document D8 also describes diaminopyrimidine derivatives, falling under the general formula of present claim 1, with polyvinylpyrrolidone as carrier (see page 9, line 21).

P-document D9 has a filing date of 24.3.99, which is before the priority date of the present application, and describes triazine derivatives falling under the general formula of present claim 1, in combination with polyvinylpyrrolidone (see example D1 on page 32).

Also P-document D11 has a filing date before the priority date of the present application. D11 discloses in example D1 on page 30 a formulation of compounds which fall under the general formula of present claim 1 and which contain polyvinylpyrrolidone.

The subject-matter of the claims differs from these documents in that the compounds constitute a **solid solution** in the polymeric matrix.

Therefore the subject-matter of the claims is novel.

It also involves an inventive step, since solid solutions of the compounds are not obvious for the person skilled in the art.

In addition, table 2 of the application shows the high dissolution rate of the





**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP00/09149

compositions of the invention.

**SECTION VI:**

Certain published documents (Rule 70.10)

Application No Patent No	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
WO 00 27828	18.5.00	4.11.99	10.11.99

**SECTION VII:**

The description has not yet been adapted to the wording of new claim 1.



Rec'd on 19 MAR 02

25

REPLACED BY

Het is a heterocycle selected from the group consisting of pyridine; pyridine substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino or aryl; pyrimidine; pyrimidine substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)-amino or aryl; tetrazole; tetrazole substituted with C<sub>1-6</sub>alkyl or aryl; triazole; triazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)-amino; thiadiazole; thiadiazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)-amino; oxadiazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino; imidazole; imidazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino; thiazole; thiazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino; oxazole; oxazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino; aryl is phenyl or phenyl substituted with C<sub>1-6</sub>alkyl or halo, and the heterocyclic radical "Het" is bound to the sulfur atom via a carbon atom,

as a solid dispersion in a polymeric matrix, wherein the polymeric matrix is consisting of a homo- or copolymer of N-vinylpyrrolidone.

2. Particles according to claim 1, wherein the copolymer of N-vinylpyrrolidone is a copolymer with vinyl acetate.
3. Particles according to claim 1 or 2, further comprising a surfactant.
4. Particles according to claim 3, wherein the surfactant is a PEG-n-hydrogenated castor oil.
5. Particles according to any of the claims 1 to 3, wherein the surfactant is a low molecular weight polyoxyethylene polyoxypropylene block copolymer.



# PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>0480/001219</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/EP 00/ 09149</b>	International filing date (day/month/year) <b>19/09/2000</b>	(Earliest) Priority Date (day/month/year) <b>24/09/1999</b>
Applicant  <b>KNOLL AKTIENGESELLSCHAFT</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/09149

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D239/48 C07D231/18 C07D239/50 C07D403/12 C07D521/00  
C07D405/14 A61K31/505 A61P35/00 A61K9/16 A61K9/14

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 872 233 A (JANSSEN) 21 October 1998 (1998-10-21)  page 1 -page 11 ---	1-5, 10-12, 14,15
Y	EP 0 834 507 A (JANSSEN) 8 April 1998 (1998-04-08) cited in the application page 1 -page 5; claims; tables 2-5 ---	1-5, 10-12, 14,15
Y	WO 99 02523 A (JANSSEN) 21 January 1999 (1999-01-21) cited in the application the whole document ---  -/--	1-5, 10-12, 14,15

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance  
 \*E\* earlier document but published on or after the international filing date  
 \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
 \*O\* document referring to an oral disclosure, use, exhibition or other means  
 \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
 \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
 \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  
 \*&\* document member of the same patent family

Date of the actual completion of the international search

17 May 2001

Date of mailing of the international search report

31/05/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Francois, J





## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/09149

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 13499 A (JANSSEN) 9 May 1996 (1996-05-09) cited in the application page 0; claims; tables 10,11 ----	1-5, 10-12, 14,15
Y	US 5 880 130 A (ANDREW PETER THOMAS) 9 March 1999 (1999-03-09)  column 37, line 10 -column 50 ----	1-5, 10-12, 14,15
Y	WO 97 19065 A (CELLTECH) 29 May 1997 (1997-05-29)  page 1 -page 15; claims ----	1-5, 10-12, 14,15
Y	WO 98 41512 A (CELLTECH) 24 September 1998 (1998-09-24)  page 1 -page 18; claims ----	1-5, 10-12, 14,15
Y	WO 91 18887 A (SMITH-KLINE) 12 December 1991 (1991-12-12)  page 1 -page 10; claims ----	1-5, 10-12, 14,15
P,Y	WO 99 50256 A (JANSSEN) 7 October 1999 (1999-10-07)  the whole document ----	1-5, 10-12, 14,15
P,Y	WO 00 27828 A (JANSSEN) 18 May 2000 (2000-05-18) cited in the application page 15; claims ----	1-5, 10-12, 14,15
P,Y	EP 0 945 443 A (JANSSEN) 29 September 1999 (1999-09-29)  the whole document -----	1-5, 10-12, 14,15



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/09149

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 872233	A	21-10-1998	NONE
EP 834507	A	08-04-1998	AU 3926697 A 09-04-1998
		BR 9704937 A 06-06-2000	
		CA 2216486 A 01-04-1998	
		CN 1180698 A 06-05-1998	
		CZ 9702993 A 11-11-1998	
		HR 970526 A 31-10-1998	
		HU 9701596 A 28-06-1999	
		JP 10114759 A 06-05-1998	
		NO 974368 A 02-04-1998	
		PL 322369 A 14-04-1998	
		SG 53075 A 28-09-1998	
		SK 131997 A 11-06-1999	
		TR 9701070 A 21-04-1998	
		TW 411335 B 11-11-2000	
		ZA 9708766 A 30-03-1999	
WO 9902523	A	21-01-1999	AU 8857598 A 08-02-1999
		AU 8857698 A 08-02-1999	
		BG 103934 A 30-11-2000	
		BR 9811676 A 19-09-2000	
		BR 9811679 A 19-09-2000	
		CN 1262675 T 09-08-2000	
		CN 1262684 T 09-08-2000	
		WO 9902496 A 21-01-1999	
		EP 1000029 A 17-05-2000	
		EP 1068200 A 17-01-2001	
		HR 20000004 A 31-12-2000	
		HR 20000007 A 31-12-2000	
		HU 0003078 A 29-01-2001	
		JP 2000515560 T 21-11-2000	
		NO 20000093 A 10-03-2000	
		PL 337648 A 28-08-2000	
		SK 182999 A 14-08-2000	
		SK 184199 A 11-07-2000	
		TR 200000020 T 21-09-2000	
WO 9613499	A	09-05-1996	AP 779 A 03-11-1999
		AT 198889 T 15-02-2001	
		AU 697744 B 15-10-1998	
		AU 3868095 A 23-05-1996	
		BG 101402 A 31-10-1997	
		BR 9509436 A 06-01-1998	
		CZ 9701198 A 18-03-1998	
		DE 69519995 D 01-03-2001	
		EP 0788496 A 13-08-1997	
		FI 971784 A 25-04-1997	
		HR 950532 A 31-08-1997	
		HU 77360 A 30-03-1998	
		IL 115771 A 29-02-2000	
		JP 3025907 B 27-03-2000	
		JP 9511759 T 25-11-1997	
		KR 227231 B 01-11-1999	
		NO 971895 A 24-04-1997	
		NZ 295353 A 26-08-1998	
		PL 319905 A 01-09-1997	
		RU 2144032 C 10-01-2000	



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/09149

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9613499 A		SK 50797 A	08-04-1998
		TR 960337 A	21-06-1996
		US 5521186 A	28-05-1996
		US 5929075 A	27-07-1999
		ZA 9509084 A	29-04-1997
US 5880130 A	09-03-1999	AU 1194895 A	27-06-1995
		EP 0733045 A	25-09-1996
		WO 9515952 A	15-06-1995
		JP 9506363 T	24-06-1997
		ZA 9409546 A	23-06-1995
WO 9719065 A	29-05-1997	AU 7631496 A	11-06-1997
		EP 0862560 A	09-09-1998
		US 5958935 A	28-09-1999
WO 9841512 A	24-09-1998	AU 6411698 A	12-10-1998
		EP 0970056 A	12-01-2000
		US 6048866 A	11-04-2000
WO 9118887 A	12-12-1991	AU 7971691 A	31-12-1991
WO 9950256 A	07-10-1999	AU 3599799 A	18-10-1999
		BR 9909197 A	05-12-2000
		EP 1066269 A	10-01-2001
		NO 20004809 A	24-11-2000
		TR 200002761 T	22-01-2001
		US 6150360 A	21-11-2000
		EP 0945447 A	29-09-1999
WO 0027828 A	18-05-2000	AU 1046200 A	29-05-2000
		WO 0122938 A	05-04-2001
EP 945443 A	29-09-1999	AU 3599699 A	18-10-1999
		BR 9909191 A	05-12-2000
		WO 9950250 A	07-10-1999
		NO 20004810 A	26-09-2000
		TR 200002760 T	21-12-2000
		US 6197779 B	06-03-2001
		EP 0945442 A	29-09-1999



(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number  
**WO 01/23362 A2**

(51) International Patent Classification<sup>7</sup>: C07D 239/48,  
251/18, 239/50, 403/12, 521/00, 405/14, A61K 31/505,  
A61P 35/00

Dannstadt (DE). ROSENBERG, Jörg [DE/DE]; Bruch-  
strasse 29, 67158 Ellerstadt (DE). BREITENBACH, Jörg  
[DE/DE]; Hans-Sachs-Ring 95A, 68199 Mannheim (DE).

(21) International Application Number: PCT/EP00/09149

(74) Agent: GOLDSCHIED, Bettina; BASF Aktiengesellschaft, 67056 Ludwigshafen (DE).

(22) International Filing Date:  
19 September 2000 (19.09.2000)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
199 45 982.7 24 September 1999 (24.09.1999) DE

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

(71) Applicant (*for all designated States except US*): KNOLL AKTIENGESELLSCHAFT [DE/DE]; 67061 Ludwigshafen (DE).

**Published:**


— Without international search report and to be republished upon receipt of that report.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): HANTKE, Thomas [DE/DE]; Landauerstrasse 5, 67067 Ludwigshafen (DE). REHBOCK, Bettina [DE/DE]; Wasgauring 28, 67125

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: RATE-CONTROLLED PARTICLES



(I)

(57) Abstract: Rate-controlled particles, comprising compounds of formula (I) as a solid dispersion.

WO 01/23362 A2

4

■

4

6



JC10 Rec'd PCT/PTO 19 MAR 2002

## Rate-controlled particles


## Specification

5

The present invention concerns pharmaceutical compositions in the form of rate-controlled particles, comprising compounds of the formula (I) to (VI)

10 (I) is an antiviral compound of formula

15



(I)

a N-oxide, a pharmaceutically acceptable addition salt or a  
20 stereochemically isomeric form thereof, wherein


- Y is CR<sup>5</sup> or N;  
A is CH, CR<sup>4</sup> or N;  
n is 0, 1, 2, 3 or 4;
- 25 Q is -NR<sup>1</sup>R<sup>2</sup> or when Y is CR<sup>5</sup> then Q may also be hydrogen;  
R<sup>1</sup> and R<sup>2</sup> are each independently selected from hydrogen, hydroxy, C<sub>1-12</sub>alkyl, C<sub>1-12</sub>alkyloxy, C<sub>1-12</sub>alkylcarbonyl, C<sub>1-12</sub>alkyloxycarbonyl, aryl, amino, mono- or di(C<sub>1-12</sub>alkyl)-amino, mono- or di(C<sub>1-12</sub>alkyl)aminocarbonyl wherein each of  
30 the aforementioned C<sub>1-12</sub>alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C<sub>1-6</sub>alkyloxy, hydroxy-C<sub>1-6</sub>alkyloxy, carboxyl, C<sub>1-6</sub>alkyloxycarbonyl, cyano, amino, imino, aminocarbonyl, aminocarbonylamino, mono- or  
35 di(C<sub>1-6</sub>alkyl)amino, aryl and Het; or  
R<sup>1</sup> and R<sup>2</sup> taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C<sub>1-12</sub>alkyl)aminoC<sub>1-4</sub>-alkylidene;  
R<sup>3</sup> is hydrogen, aryl, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy-carbonyl, C<sub>1-6</sub>alkyl substituted with C<sub>1-6</sub>alkyloxycarbonyl; and  
40 each R<sup>4</sup> independently is hydroxy, halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy, or when Y is CR<sup>5</sup> then R<sup>4</sup> may also represent C<sub>1-6</sub>alkyl substituted with cyano or aminocarbonyl;
- 45 R<sup>5</sup> is hydrogen or C<sub>1-4</sub>alkyl;  
L is -X<sup>1</sup>-R<sup>6</sup> or -X<sup>2</sup>-Alk-R<sup>7</sup> wherein

- $R^6$  and  $R^7$  each independently are phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkyloxy,  $C_{1-6}$ alkylcarbonyl,  $C_{1-6}$ alkyloxycarbonyl, formyl, cyano, nitro, amino, and trifluoromethyl; or when Y is  $CR^5$  then  $R^6$  and  $R^7$  may also be selected from phenyl substituted with one, two, three, four or five substituents each independently selected from aminocarbonyl, trihalomethyloxy and trihalomethyl; or when Y is N then  $R^6$  and  $R^7$  may also be selected from indanyl or indolyl, each of said indanyl or indolyl may be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkyloxy,  $C_{1-6}$ alkylcarbonyl,  $C_{1-6}$ alkyloxycarbonyl, formyl, cyano, nitro, amino, and trifluoromethyl;
- $X^1$  and  $X^2$  are each independently  $-NR^3-$ ,  $-NH-NH-$ ,  $-N=N-$ ,  $-O-$ ,  $-S-$ ,  $-S(=O)-$  or  $-S(=O)_2-$ ;
- Alk is  $C_{1-4}$ alkanediyl; or
- when Y is  $CR^5$  then L may also be selected from  $C_{1-10}$ alkyl,  $C_{3-10}$ alkenyl,  $C_{3-10}$ alkynyl,  $C_{3-7}$ cycloalkyl, or  $C_{1-10}$ alkyl substituted with one or two substituents independently selected from  $C_{3-7}$ cycloalkyl, indanyl, indolyl and phenyl, wherein said phenyl, indanyl and indolyl may be substituted with one, two, three, four or where possible five substituents each independently selected from halo, hydroxy,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkyloxy, cyano, aminocarbonyl,  $C_{1-6}$ alkyloxycarbonyl, formyl, nitro, amino, trihalomethyl, trihalomethyloxy and  $C_{1-6}$ alkylcarbonyl;
- aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkyloxy, cyano, nitro and trifluoromethyl;
- Het is an aliphatic or aromatic heterocyclic radical; said aliphatic heterocyclic radical is selected from pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl wherein each of said aliphatic heterocyclic radical may optionally be substituted with an oxo group; and said aromatic heterocyclic radical is selected from pyrrolyl, furanyl, thienyl, pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocyclic radical may optionally be substituted with hydroxy.

The compounds of formula (I) can be prepared according to the methods described in the patent applications with application number PCT/EP99/02043 and PCT/EP99/02044.

3

(II) is an antiviral compound of formula



10 the *N*-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein

-b¹=b²-C(R²ᵃ)=b³-b⁴= represents a bivalent radical of formula

-CH=CH-C(R²ᵃ)=CH-CH= (b-1);

15 -N=CH-C(R²ᵃ)=CH-CH= (b-2);

-CH=N-C(R²ᵃ)=CH-CH= (b-3);

-N=CH-C(R²ᵃ)=N-CH= (b-4);

-N=CH-C(R²ᵃ)=CH-N= (b-5);

-CH=N-C(R²ᵃ)=N-CH= (b-6);

20 -N=N-C(R²ᵃ)=CH-CH= (b-7);


q is 0, 1, 2; or where possible q is 3 or 4;

R¹ is hydrogen, aryl, formyl, C₁-₆alkylcarbonyl, C₁-₆alkyl, C₁-₆alkyloxycarbonyl, C₁-₆alkyl substituted with formyl, C₁-₆alkylcarbonyl, C₁-₆alkyloxycarbonyl;

25 R²ᵃ is cyano, aminocarbonyl, mono- or di(methyl)aminocarbonyl, C₁-₆alkyl substituted with cyano, aminocarbonyl or mono- or di(methyl)aminocarbonyl, C₂-₆alkenyl substituted with cyano, or C₂-₆alkynyl substituted with cyano;

each R² independently is hydroxy, halo, C₁-₆alkyl optionally substituted with cyano or -C(=O)R⁶, C₃-₇cycloalkyl, C₂-₆alkenyl optionally substituted with one or more halogen atoms or cyano, C₂-₆alkynyl optionally substituted with one or more halogen atoms or cyano, C₁-₆alkyloxy, C₁-₆alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C₁-₆alkyl)amino,

35 polyhalomethyl, polyhalomethoxy, polyhalomethylthio, -S(=O)ₚR⁶, -NH-S(=O)ₚR⁶, -C(=O)R⁶, -NHC(=O)H, -C(=O)NHNH₂, -NHC(=O)R⁶, -C(=NH)R⁶ or a radical of formula



wherein each A independently is N, CH or CR⁶;

B is NH, O, S or NR⁶;

45 p is 1 or 2; and

R⁶ is methyl, amino, mono- or dimethylamino or polyhalomethyl;

- L is C<sub>1-10</sub>alkyl, C<sub>2-10</sub>alkenyl, C<sub>2-10</sub>alkynyl, C<sub>3-7</sub>cycloalkyl, whereby each of said aliphatic group may be substituted with one or two substituents independently selected from
- \* C<sub>3-7</sub>cycloalkyl,
  - 5 \* indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo, C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and C<sub>1-6</sub>alkylcarbonyl,
  - 10 \* phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R<sup>2</sup>; or
- 15 L is -X-R<sup>3</sup> wherein
- R<sup>3</sup> is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R<sup>2</sup>; and
- 20 X is -NR<sup>1</sup>-, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)- or -S(=O)<sub>2</sub>-;
- Q represents hydrogen, C<sub>1-6</sub>alkyl, halo, polyhaloC<sub>1-6</sub>alkyl or -NR<sup>4</sup>R<sup>5</sup>; and
- 25 R<sup>4</sup> and R<sup>5</sup> are each independently selected from hydrogen, hydroxy, C<sub>1-12</sub>alkyl, C<sub>1-12</sub>alkyloxy, C<sub>1-12</sub>alkylcarbonyl, C<sub>1-12</sub>alkyloxy-carbonyl, aryl, amino, mono- or di(C<sub>1-12</sub>alkyl)amino, mono- or di(C<sub>1-12</sub>alkyl)aminocarbonyl wherein each of the aforementioned C<sub>1-12</sub>alkyl groups may optionally and each individually be
- 30 substituted with one or two substituents each independently selected from hydroxy, C<sub>1-6</sub>alkyloxy, hydroxyC<sub>1-6</sub>alkyloxy, carboxyl, C<sub>1-6</sub>alkyloxycarbonyl, cyano, amino, imino, mono- or di(C<sub>1-6</sub>alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)<sub>p</sub>R<sup>6</sup>, -NH-S(=O)<sub>p</sub>R<sup>6</sup>, -C(=O)R<sup>6</sup>, -NHC(=O)H, -C(=O)NHNH<sub>2</sub>, -NHC(=O)R<sup>6</sup>, -C(=NH)R<sup>6</sup>, aryl and Het; or
- 35 R<sup>4</sup> and R<sup>5</sup> taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C<sub>1-12</sub>alkyl)aminoC<sub>1-4</sub>alkylidene;
- Y represents hydroxy, halo, C<sub>3-7</sub>cycloalkyl, C<sub>2-6</sub>alkenyl optionally substituted with one or more halogen atoms, C<sub>2-6</sub>alkynyl
- 40 optionally substituted with one or more halogen atoms, C<sub>1-6</sub>alkyl substituted with cyano or -C(=O)R<sup>6</sup>, C<sub>1-6</sub>alkyloxy, C<sub>1-6</sub>alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C<sub>1-6</sub>alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)<sub>p</sub>R<sup>6</sup>, -NH-S(=O)<sub>p</sub>R<sup>6</sup>, -C(=O)R<sup>6</sup>, -NHC(=O)H, -C(=O)NHNH<sub>2</sub>, -NHC(=O)R<sup>6</sup>, -C(=NH)R<sup>6</sup> or aryl;
- 45


aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>1-6</sub>alkyloxy, cyano, nitro, polyhaloC<sub>1-6</sub>alkyl and polyhaloC<sub>1-6</sub>alkyloxy;

- 5 Het is an aliphatic or aromatic heterocyclic radical; said aliphatic heterocyclic radical is selected from pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl wherein each of said aliphatic heterocyclic radical may optionally be substituted with an oxo group; and said aromatic heterocyclic radical is selected from pyrrolyl, furanyl, thienyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocyclic radical may optionally be substituted with hydroxy.

15

The compounds of formula (II) can be prepared according to the methods described in the US patent applications with application number 60/143962 and 60/107792.

- 20 (III) is an antiviral compound of formula



a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein

- 30 -a<sup>1</sup>=a<sup>2</sup>-a<sup>3</sup>=a<sup>4</sup>- represents a bivalent radical of formula

-CH=CH-CH=CH- (a-1);

-N=CH-CH=CH- (a-2);

-N=CH-N=CH- (a-3);

-N=CH-CH=N- (a-4);

- 35 -N=N-CH=CH- (a-5);


n is 0, 1, 2, 3 or 4; and in case -a<sup>1</sup>=a<sup>2</sup>-a<sup>3</sup>=a<sup>4</sup>- is (a-1), then n may also be 5;

R<sup>1</sup> is hydrogen, aryl, formyl, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxycarbonyl, C<sub>1-6</sub>alkyl substituted with formyl, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyloxycarbonyl; and

- 40 each R<sup>2</sup> independently is hydroxy, halo, C<sub>1-6</sub>alkyl optionally substituted with cyano or -C(=O)R<sup>4</sup>, C<sub>3-7</sub>cycloalkyl, C<sub>2-6</sub>alkenyl optionally substituted with one or more halogen atoms or cyano, C<sub>2-6</sub>alkynyl optionally substituted with one or more halogen atoms or cyano, C<sub>1-6</sub>alkyloxy, C<sub>1-6</sub>alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C<sub>1-6</sub>alkyl)amino,
- 45

polyhalomethyl, polyhalomethoxy, polyhalomethylthio,  
 $-S(=O)_pR^4$ ,  $-NH-S(=O)_pR^4$ ,  $-C(=O)R^4$ ,  $-NHC(=O)H$ ,  $-C(=O)NHNH_2$ ,  
 $-NHC(=O)R^4$ ,  $-C(=NH)R^4$  or a radical of formula

5



(c)

wherein each A independently is N, CH or  $CR^4$ ;

B is NH, O, S or  $NR^4$ ;

10 p is 1 or 2; and

$R^4$  is methyl, amino, mono- or dimethylamino or polyhalo-  
 methyl;

L is  $C_{4-10}$ alkyl,  $C_{2-10}$ alkenyl,  $C_{2-10}$ alkynyl,  $C_{3-7}$ cycloalkyl,  
 whereby each of said aliphatic group may be substituted with  
 15 one or two substituents independently selected from

\*  $C_{3-7}$ cycloalkyl,

\* indolyl or isoindolyl, each optionally substituted with  
 one, two, three or four substituents each independently  
 selected from halo,  $C_{1-6}$ alkyl, hydroxy,  $C_{1-6}$ alkyloxy,  
 20 cyano, aminocarbonyl, nitro, amino, polyhalomethyl, poly-  
 halomethoxy and  $C_{1-6}$ alkylcarbonyl,

\* phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl,  
 wherein each of said aromatic rings may optionally be  
 substituted with one, two, three, four or five substi-  
 25 tuents each independently selected from the substituents  
 defined in  $R^2$ ; or

L is  $-X-R^3$  wherein


$R^3$  is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazi-  
 nyl, wherein each of said aromatic rings may optionally  
 30 be substituted with two, three, four or five substituents  
 each independently selected from the substituents defined  
 in  $R^2$ ; and

X is  $-NR^1-$ ,  $-NH-NH-$ ,  $-N=N-$ ,  $-O-$ ,  $-C(=O)-$ ,  $-CHOH-$ ,  $-S-$ ,  
 $-S(=O)-$  or  $-S(=O)_2-$ ;

35 aryl is phenyl or phenyl substituted with one, two, three, four  
 or five substituents each independently selected from halo,  
 $C_{1-6}$ alkyl,  $C_{3-7}$ cycloalkyl,  $C_{1-6}$ alkyloxy, cyano, nitro, poly-  
 halo $C_{1-6}$ alkyl and polyhalo $C_{1-6}$ alkyloxy.

40 The compounds of formula (III) can be prepared according to the  
 methods described in the US patent application with application  
 number 60/107799.

(IV) is an antiviral compound of formula



(IV)

10

the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein

$R^1$  and  $R^2$  are each independently selected from hydrogen; hydroxy; amino;  $C_{1-6}$ alkyl;  $C_{1-6}$ alkyloxy;  $C_{1-6}$ alkylcarbonyl;  $C_{1-6}$ alkyloxycarbonyl;  $Ar^1$ ; mono- or di( $C_{1-6}$ alkyl)amino; mono- or di( $C_{1-6}$ alkyl)aminocarbonyl; dihydro-2(3H)-furanone;  $C_{1-6}$ alkyl substituted with one or two substituents each independently selected from amino, imino, aminocarbonyl, aminocarbonylamino, hydroxy, hydroxy $C_{1-6}$ alkyloxy, carboxyl, mono- or di( $C_{1-6}$ alkyl)amino,  $C_{1-6}$ alkyloxycarbonyl and thienyl; or  $R^1$  and  $R^2$  taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di( $C_{1-6}$ alkyl)amino $C_{1-4}$ alkylidene;

$R^3$  is hydrogen,  $Ar^1$ ,  $C_{1-6}$ alkylcarbonyl,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkyloxycarbonyl,  $C_{1-6}$ alkyl substituted with  $C_{1-6}$ alkyloxycarbonyl; and  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$  and  $R^8$  are each independently selected from hydrogen, hydroxy, halo,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy;

$L$  is  $C_{1-10}$ alkyl;  $C_{3-10}$ alkenyl;  $C_{3-10}$ alkynyl;  $C_{3-7}$ cycloalkyl; or  $L$  is  $C_{1-10}$ alkyl substituted with one or two substituents independently selected from  $C_{3-7}$ cycloalkyl; indolyl or indolyl substituted with one, two, three or four substituents each independently selected from halo,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy,  $C_{1-6}$ alkylcarbonyl; phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy,  $C_{1-6}$ alkylcarbonyl; and,

$Ar^1$  is phenyl, or phenyl substituted with one, two or three substituents each independently selected from halo,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkyloxy, cyano, nitro or trifluoromethyl; with the proviso that compounds (a) to (o)


45

Co. No.	Alk	R <sup>1</sup> /R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	R <sup>8</sup>
5	a	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	CH <sub>3</sub>	H	H	H
	b	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	H	H	NO <sub>2</sub>	H
	c	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	C <sub>6</sub> H <sub>5</sub>	H	H	H	H
	d	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	NO <sub>2</sub>	H	CH <sub>3</sub>	H
	e	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	H	H	NH <sub>2</sub>	H
10	f	4-(2-methylpropyl)phenylmethyl	H/H	H	H	CF <sub>3</sub>	H	H
	g	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	H	H	Cl	H
	h	4-(2-methylpropyl)phenylmethyl	H/H	H	H	H	H	H
	i	3,4-dimethoxyphenylmethyl	H/H	H	H	H	H	H
	j	2,3-dimethoxyphenylmethyl	H/H	H	H	H	H	H
15	k	3,4-diethoxyphenylmethyl	H/H	H	H	H	H	H
	l	2-(3,5-(1,1-dimethylethyl)-4-hydroxy-phenyl)ethyl	H/H	H	H	H	H	H
	m	2-(3,5-(1,1-dimethylethyl)-4-hydroxy-phenyl)ethyl	H/H	H	H	t-Bu	OH	t-Bu
	n	Phenylmethyl	H/H	H	CH <sub>3</sub>	H	H	H
	o	Phenylmethyl	H/H	H	H	H	H	H

20 are not included.

The compounds of formula (IV) can be prepared according to the methods described in EP-A-0834507.

25 (V) is an antifungal compound of formula



the N-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein

n is zero, 1, 2 or 3;

40 X is N or CH;

each R<sup>1</sup> independently is halo, nitro, cyano, amino, hydroxy, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy or trifluoromethyl;


R<sup>2</sup> is hydrogen; C<sub>3-7</sub>alkenyl; C<sub>3-7</sub>alkynyl, aryl; C<sub>3-7</sub>cycloalkyl; C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkyl substituted with hydroxy, C<sub>1-4</sub>alkyloxy, C<sub>3-7</sub>cycloalkyl or aryl;

45

R<sup>3</sup> and R<sup>4</sup> each independently are hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl or aryl; or



R<sup>3</sup> and R<sup>4</sup> taken together form a bivalent radical -R<sup>3</sup>-R<sup>4</sup>- of formula:



10


wherein R<sup>5a</sup>, R<sup>5b</sup>, R<sup>5c</sup>, R<sup>5d</sup> each independently are hydrogen, C<sub>1-6</sub>alkyl or aryl; and

aryl is phenyl or phenyl substituted with one, two or three substituents selected from halo, nitro, cyano, amino, hydroxy,

15 C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy or trifluoromethyl.


The compounds of formula (V) can be prepared according to the methods described in WO 99/02523.

20 (VI) is an apolipoprotein-B synthesis inhibitor of formula



30

the N-oxides, the stereochemically isomeric forms thereof, and the pharmaceutically acceptable acid addition salts, wherein A and B taken together form a bivalent radical of formula :



40 in the bivalent radicals of formula (a) and (b) the hydrogen atom may be replaced by C<sub>1-6</sub>alkyl; in the bivalent radicals of formula (c), (d), (e), (f), one or two hydrogen atoms may be replaced by C<sub>1-6</sub>alkyl;

R<sup>1</sup> is hydrogen, C<sub>1-6</sub>alkyl or halo;

45 R<sup>2</sup> is hydrogen or halo;

R<sup>3</sup> is hydrogen; C<sub>1-8</sub>alkyl; C<sub>3-6</sub>cycloalkyl; or C<sub>1-8</sub>alkyl substituted with hydroxy, oxo, C<sub>3-6</sub>cycloalkyl or aryl;

- Het is a heterocycle selected from the group consisting of pyridine; pyridine substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino or aryl; pyrimidine;
- 5 pyrimidine substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)-amino or aryl; tetrazole; tetrazole substituted with C<sub>1-6</sub>alkyl or aryl; triazole; triazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl,
- 10 hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)-amino; thiadiazole; thiadiazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)-amino; oxadiazole substituted with one or two substituents
- 15 selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino; imidazole; imidazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino; thiazole; thiazole substituted with one or
- 20 two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino; oxazole; oxazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino;
- 25 aryl is phenyl or phenyl substituted with C<sub>1-6</sub>alkyl or halo.

The heterocyclic radical "Het" is bound to the sulfur atom via a carbon atom.

- 30 The compounds of formula (VI) can be prepared according to the methods described in WO 96/13499.

- The particles comprise the compounds of formula (I) to (VI) as a solid dispersion in a polymeric matrix, wherein the poly-
- 35 meric matrix is consisting of a homo- or copolymer of N-vinylpyrrolidone. Furthermore, the invention concerns a process for manufacturing of such particles and pharmaceutical dosage forms comprising such particles.

- 40 The compounds of formula (I) to (VI) contained in the particles show poor bio-availability.

- In order to improve the dissolution characteristics the compounds are dispersed in a polymeric matrix, preferably by using a melt-
- 45 extrusion process.

EP-A 0 240 904 discloses a method for producing solid pharmaceutical forms by extrusion of polymer melts which contain active substances, using as polymers homo- or copolymers of N-vinylpyrrolidone.

5

EP-B 0 580 860 discloses a method for producing solid dispersions of drug substances in a polymeric matrix using a twin screw extruder.

- 10 It is an object of the present invention to provide rate-controlled pharmaceutical forms containing the aforementioned compounds.

We have found that this object is achieved by the particles

- 15 defined at the outset.

Preferred compounds according to the invention are:

4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;

- 20 4-[[2-[(cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile;

4-[[4-amino-5-chloro-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]-amino]benzonitrile;

4-[[5-chloro-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]-amino]benzonitrile;

- 25 4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-amino]benzonitrile;

4-[[4-amino-5-chloro-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;

- 30 4-[[5-bromo-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]-amino]benzonitrile;

4-[[4-amino-5-chloro-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile;

4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile;

- 35 4-[[4-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazin-2-yl]amino]benzonitrile;

4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-1,3,5-triazin-2-yl]-amino]benzonitrile;

- 40 4-[[4-[(2,6-dichlorophenyl)methyl]-6-(hydroxyamino)-1,3,5-triazin-2-yl]amino]benzonitrile;

1-[4-[4-[4-[(2,4-difluorophenyl)-4-(1H-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-2-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-3-(1-methylethyl)-2-imidazolidinone;

45

(-)-[2S-[2alpha,4alpha(S\*)]]-4-[4-[4-[4-[[2-(4-chlorophenyl)-2-[[[(4-methyl-4H-1,2,4-triazol-3-yl)thio]methyl]-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methyl-propyl)-3H-1,2,4-triazol-3-one,

- 5 a N-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof.

According to the present invention the term "rate-controlled" means that depending on the composition of the matrix the

- 10 particles can show instant release of the active ingredient or modified release (sustained release).

The compounds according to the invention are homogeneously dispersed in a polymer matrix consisting of a homopolymer of  
15 N-vinylpyrrolidone or, preferably, a copolymer of N-vinylpyrrolidone. A preferred copolymer is a copolymer of N-vinylpyrrolidone and vinyl acetate, especially a copolymer obtained from 60% b.w. of NVP and 40% b.w. of vinylacetate.

- 20 The polymers show Fikentscher K values of from 17 to 90, preferably a K value of 30 (for the definition of the K value see "H. Fikentscher, Cellulose-Chemie" (1932), 58-64 and 71-74).

The polymeric matrix component is used in amounts of from 40 to  
25 70, preferably of from 50 to 65% b.w. of the total weight of the particles.

- In a preferred embodiment of the invention the polymeric matrix further comprises a surfactant, preferably a surfactant with  
30 a HLB-value of 10-18 (HLB: Hydrophilic Lipophilic Balance). Especially preferred surfactants are selected from the group consisting of low molecular weight polyoxyethylene polyoxypropylene block copolymers with a mean molecular weight of 1000 to 6000 g/mol, and hydrogenated castor oil which can be  
35 modified with polyethylene glycol.

The amounts of surfactants used lies in the range of up to 20% b.w., preferably 5 to 15% b.w., of the particles.

- 40 In another preferred embodiment the matrix further comprises an organic carboxylic acid in amounts of up to 5% b.w. of the particles.

In another preferred embodiment of the invention the polymeric matrix further comprises hydroxypropyl methyl cellulose in  
45 amounts of up to 25% b.w., preferably from 5 to 10% b.w..

The particles of the present invention are prepared as solid dispersions of the active compounds in a polymeric matrix. The term "solid dispersion" is well known in the art and means a dispersion consisting of solid components. Preferably solid  
5 dispersions are in the form of solid solutions wherein the active ingredients are molecularly dispersed in the polymeric matrix.

Such solid dispersion is preferably obtained by forming a homogeneous mixture of the components in the form of a melt,  
10 extruding said melt and shaping of the extrudate. The melting is effected by the input of thermal and/or mechanic energy.

Depending on the composition of the matrix, the melting takes place in the range of from 40°C to 190°C, preferably 50 to 150°C.  
15 The suitable temperature range depends on the glass transition temperature of the polymer component, the properties of the active ingredients and further additives. The optimal temperature range can be established by a few simple tests.

20 The mixing of the active substances with the polymer and additional components of the matrix can take place before or after the melting of the polymer. Preferably the process is solvent-free which means that no additional organic solvents or water are added.

25 The plastification and melting preferably can take place in an extruder, a kneader or a mixing reactor, preferably in an extruder having one or more screws which may rotate in the same direction or opposite directions, especially in a twin screw  
30 extruder. The latter can be operated with or without kneading elements, but use of kneading elements is preferred because mixing is better.

The still plastic material is extruded through a die or a breaker  
35 plate and then shaped into particles. This may be effected by milling and subsequent sieving the cooled extrudate. The preferred particle size for instant release forms lies in the range of from 0.5 to 1.5 mm.

40 The particles, optionally together with conventional pharmaceutically acceptable excipients, may be further processed to conventional pharmaceutical dosage forms such as tablets, pastilles, suppositories, or be packed in capsules.

45 It is possible and particularly advantageous to produce pharmaceutical forms with rate-controlled release and improved dissolution rates of the active ingredients. This was not to be

expected in view of the low solubility of the active ingredients in aqueous media.

#### Examples

5

#### General method

Powder mixes of the components were melt kneaded at 145°C for 5 min.. After cooling the solidified melts were ground and  
10 sieved. The sieve fraction 0.5-1.5 mm was used for the dissolution tests.

The composition of the individual powder mixes is listed in Table 1.

15

Table 1

Example No.	1	2	3	4	5	6
Active ingredient <sup>1)</sup>	30	30	30	30	30	40
20 VP-VAC-copolymer <sup>2)</sup>	65	55	55	60	55	47,1
Surfactant <sup>3)</sup>	5	15		5	5	4,3
Citric acid				5		
HPMC					10	8,6
Surfactant <sup>4)</sup>			15			

25 <sup>1)</sup> 4-[[4-[2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]-benzonitrile

<sup>2)</sup> Kollidon® VA64, VP/VAC = 60/40, BASF Aktiengesellschaft

<sup>3)</sup> PEG-n-hydrogenated Castoroil

<sup>4)</sup> polyoxyethylene polyoxypropylene blockcopolymer, mean mol.  
30 weight 4000 g/mol

The dissolution tests were carried out according to USP XXIII, paddle model, pH no change test, 0.1 M HCl, at 37°C, 100 rpm

35

40

45

The results are listed in Table 2.

Table 2: Dissolution Rates of particles according to examples 1-6

5

time [min]	Dissolution [%]				time [min]	Dissolution [%]	
	Ex. 1 (IR)	Ex. 2 (IR)	Ex. 3 (IR)	Ex. 4 (IR)		Ex. 5 (SR)	Ex. 6 (SR)
5	53	65	58	57	1		
10	73	86	88	82	2		
15	77	91	95	89	3		
20	81	91	96	93	4		
30	87	94	99	94	6		
15	60	92	93	96	8	96	95
120	93	94	97	95			
	IR: Instant Release					SR: Sustained Release	

20 DSC-Measurements were performed with the formulations according to examples 1 to 6 in open pans (air) at temperatures of from 20 → 250°C, with a heating rate of 10°C per minute. There is no indication of crystalline drug substance in the solid dispersions.

25

30

35


40

45

## Claims

1. Rate-controlled release particles, comprising a compound of  
 5 formula I

10



a N-oxide, a pharmaceutically acceptable addition salt or a  
 stereochemically isomeric form thereof, wherein

15

Y is CR<sup>5</sup> or N;

A is CH, CR<sup>4</sup> or N;

n is 0, 1, 2, 3 or 4;

20

Q is -NR<sup>1</sup>R<sup>2</sup> or when Y is CR<sup>5</sup> then Q may also be hydrogen;

R<sup>1</sup> and R<sup>2</sup> are each independently selected from hydrogen,  
 hydroxy, C<sub>1-12</sub>alkyl, C<sub>1-12</sub>alkyloxy, C<sub>1-12</sub>alkylcarbonyl,  
 C<sub>1-12</sub>alkyloxycarbonyl, aryl, amino, mono- or  
 di(C<sub>1-12</sub>alkyl)-amino, mono- or di(C<sub>1-12</sub>alkyl)aminocarbonyl  
 wherein each of the aforementioned C<sub>1-12</sub>alkyl groups may  
 optionally and each individually be substituted with one  
 or two substituents each independently selected from  
 hydroxy, C<sub>1-6</sub>alkyloxy, hydroxy-C<sub>1-6</sub>alkyloxy, carboxyl,  
 C<sub>1-6</sub>alkyloxycarbonyl, cyano, amino, imino, aminocarbonyl,  
 aminocarbonylamino, mono- or di(C<sub>1-6</sub>alkyl)amino, aryl and  
 Het; or

30

R<sup>1</sup> and R<sup>2</sup> taken together may form pyrrolidinyl, piperidinyl,  
 morpholinyl, azido or mono- or di(C<sub>1-12</sub>alkyl)aminoC<sub>1-4</sub>-  
 alkylidene;

35

R<sup>3</sup> is hydrogen, aryl, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl-  
 oxycarbonyl, C<sub>1-6</sub>alkyl substituted with C<sub>1-6</sub>alkyloxy-  
 carbonyl; and

each R<sup>4</sup> independently is hydroxy, halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl-  
 oxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl,  
 trihalomethyloxy, or when Y is CR<sup>5</sup> then R<sup>4</sup> may also  
 represent C<sub>1-6</sub>alkyl substituted with cyano or amino-  
 carbonyl;

40

R<sup>5</sup> is hydrogen or C<sub>1-4</sub>alkyl;

L is -X<sup>1</sup>-R<sup>6</sup> or -X<sup>2</sup>-Alk-R<sup>7</sup> wherein

45


R<sup>6</sup> and R<sup>7</sup> each independently are phenyl or phenyl substi-  
 tuted with one, two, three, four or five substituents  
 each independently selected from halo, hydroxy,



5 C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyl-  
oxycarbonyl, formyl, cyano, nitro, amino, and tri-  
fluoromethyl; or when Y is CR<sup>5</sup> then R<sup>6</sup> and R<sup>7</sup> may  
also be selected from phenyl substituted with one,  
two, three, four or five substituents each indepen-  
dently selected from aminocarbonyl, trihalomethyloxy  
and trihalomethyl; or when Y is N then R<sup>6</sup> and R<sup>7</sup> may  
also be selected from indanyl or indolyl, each of  
said indanyl or indolyl may be substituted with one,  
two, three, four or five substituents each  
independently selected from halo, hydroxy, C<sub>1-6</sub>alkyl,  
C<sub>1-6</sub>alkyloxy, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyloxycarbonyl,  
formyl, cyano, nitro, amino, and trifluoromethyl;  
10 X<sup>1</sup> and X<sup>2</sup> are each independently -NR<sup>3</sup>-, -NH-NH-, -N=N-,  
-O-, -S-, -S(=O)- or -S(=O)<sub>2</sub>-;  
15 Alk is C<sub>1-4</sub>alkanediyl; or  
when Y is CR<sup>5</sup> then L may also be selected from C<sub>1-10</sub>alkyl,  
C<sub>3-10</sub>alkenyl, C<sub>3-10</sub>alkynyl, C<sub>3-7</sub>cycloalkyl, or C<sub>1-10</sub>alkyl  
substituted with one or two substituents independently  
selected from C<sub>3-7</sub>cycloalkyl, indanyl, indolyl and  
20 phenyl, wherein said phenyl, indanyl and indolyl may be  
substituted with one, two, three, four or where possible  
five substituents each independently selected from halo,  
hydroxy, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, aminocarbonyl,  
C<sub>1-6</sub>alkyloxycarbonyl, formyl, nitro, amino, trihalomethyl,  
25 trihalomethyloxy and C<sub>1-6</sub>alkylcarbonyl;  
aryl is phenyl or phenyl substituted with one, two, three,  
four or five substituents each independently selected  
from halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, nitro and  
30 trifluoromethyl;  
Het is an aliphatic or aromatic heterocyclic radical;  
said aliphatic heterocyclic radical is selected from  
pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl,  
morpholinyl, tetrahydrofuranyl and tetrahydrothienyl  
35 wherein each of said aliphatic heterocyclic radical may  
optionally be substituted with an oxo group; and said  
aromatic heterocyclic radical is selected from pyrrolyl,  
furanyl, thienyl, pyridyl, pyrimidinyl, pyrazinyl and  
pyridazinyl wherein each of said aromatic heterocyclic  
40 radical may optionally be substituted with hydroxy,

or a compound of formula

5



(II)

10 the *N*-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein

-b<sup>1</sup>=b<sup>2</sup>-C(R<sup>2a</sup>)=b<sup>3</sup>-b<sup>4</sup>= represents a bivalent radical of formula

15

-CH=CH-C(R<sup>2a</sup>)=CH-CH= (b-1);

-N=CH-C(R<sup>2a</sup>)=CH-CH= (b-2);

-CH=N-C(R<sup>2a</sup>)=CH-CH= (b-3);

-N=CH-C(R<sup>2a</sup>)=N-CH= (b-4);

-N=CH-C(R<sup>2a</sup>)=CH-N= (b-5);

-CH=N-C(R<sup>2a</sup>)=N-CH= (b-6);

20

-N=N-C(R<sup>2a</sup>)=CH-CH= (b-7);

q is 0, 1, 2; or where possible q is 3 or 4;

R<sup>1</sup> is hydrogen, aryl, formyl, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxycarbonyl, C<sub>1-6</sub>alkyl substituted with formyl, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyloxycarbonyl;


25

R<sup>2a</sup> is cyano, aminocarbonyl, mono- or di(methyl)amino-carbonyl, C<sub>1-6</sub>alkyl substituted with cyano, amino-carbonyl or mono- or di(methyl)aminocarbonyl, C<sub>2-6</sub>alkenyl substituted with cyano, or C<sub>2-6</sub>alkynyl substituted with cyano;

30

each R<sup>2</sup> independently is hydroxy, halo, C<sub>1-6</sub>alkyl optionally substituted with cyano or -C(=O)R<sup>6</sup>, C<sub>3-7</sub>cycloalkyl, C<sub>2-6</sub>alkenyl optionally substituted with one or more halogen atoms or cyano, C<sub>2-6</sub>alkynyl optionally substituted with one or more halogen atoms or cyano, C<sub>1-6</sub>alkyloxy, C<sub>1-6</sub>alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C<sub>1-6</sub>alkyl)amino, polyhalomethyl, polyhalomethoxy, polyhalomethylthio, -S(=O)<sub>p</sub>R<sup>6</sup>, -NH-S(=O)<sub>p</sub>R<sup>6</sup>, -C(=O)R<sup>6</sup>, -NHC(=O)H, -C(=O)NHNH<sub>2</sub>, -NHC(=O)R<sup>6</sup>, -C(=NH)R<sup>6</sup> or a radical of formula

40



(c)

45

wherein each A independently is N, CH or CR<sup>6</sup>;

B is NH, O, S or NR<sup>6</sup>;

p is 1 or 2; and

R<sup>6</sup> is methyl, amino, mono- or dimethylamino or polyhalomethyl;

5

L is C<sub>1-10</sub>alkyl, C<sub>2-10</sub>alkenyl, C<sub>2-10</sub>alkynyl, C<sub>3-7</sub>cycloalkyl, whereby each of said aliphatic group may be substituted with one or two substituents independently selected from

10

\* C<sub>3-7</sub>cycloalkyl,

\* indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo, C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and C<sub>1-6</sub>alkyl-carbonyl,

15

\* phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R<sup>2</sup>; or

20

L is -X-R<sup>3</sup> wherein

R<sup>3</sup> is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R<sup>2</sup>; and

25

X is -NR<sup>1</sup>-, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)- or -S(=O)<sub>2</sub>-;

30

Q represents hydrogen, C<sub>1-6</sub>alkyl, halo, polyhaloC<sub>1-6</sub>alkyl or -NR<sup>4</sup>R<sup>5</sup>; and

R<sup>4</sup> and R<sup>5</sup> are each independently selected from hydrogen, hydroxy, C<sub>1-12</sub>alkyl, C<sub>1-12</sub>alkyloxy, C<sub>1-12</sub>alkylcarbonyl, C<sub>1-12</sub>alkyloxy carbonyl, aryl, amino, mono- or di(C<sub>1-12</sub>alkyl)amino, mono- or di(C<sub>1-12</sub>alkyl)aminocarbonyl wherein each of the aforementioned C<sub>1-12</sub>alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C<sub>1-6</sub>alkyloxy, hydroxyC<sub>1-6</sub>alkyloxy, carboxyl, C<sub>1-6</sub>alkyloxy carbonyl, cyano, amino, imino, mono- or di(C<sub>1-6</sub>alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)<sub>p</sub>R<sup>6</sup>, -NH-S(=O)<sub>p</sub>R<sup>6</sup>, -C(=O)R<sup>6</sup>, -NHC(=O)H, -C(=O)NHNH<sub>2</sub>, -NHC(=O)R<sup>6</sup>, -C(=NH)R<sup>6</sup>, aryl and Het; or


35

40

R<sup>4</sup> and R<sup>5</sup> taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C<sub>1-12</sub>alkyl)aminoC<sub>1-4</sub>-alkylidene;

45

- Y represents hydroxy, halo, C<sub>3-7</sub>cycloalkyl, C<sub>2-6</sub>alkenyl optionally substituted with one or more halogen atoms, C<sub>2-6</sub>alkynyl optionally substituted with one or more halogen atoms, C<sub>1-6</sub>alkyl substituted with cyano or
- 5 -C(=O)R<sup>6</sup>, C<sub>1-6</sub>alkyloxy, C<sub>1-6</sub>alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C<sub>1-6</sub>alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)<sub>p</sub>R<sup>6</sup>, -NH-S(=O)<sub>p</sub>R<sup>6</sup>, -C(=O)R<sup>6</sup>, -NHC(=O)H, -C(=O)NHNH<sub>2</sub>, -NHC(=O)R<sup>6</sup>, -C(=NH)R<sup>6</sup> or aryl;
- 10 aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>1-6</sub>alkyloxy, cyano, nitro, polyhaloC<sub>1-6</sub>alkyl and polyhaloC<sub>1-6</sub>alkyloxy;
- Het is an aliphatic or aromatic heterocyclic radical;
- 15 said aliphatic heterocyclic radical is selected from pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl wherein each of said aliphatic heterocyclic radical may optionally be substituted with an oxo group; and said
- 20 aromatic heterocyclic radical is selected from pyrrolyl, furanyl, thienyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocyclic radical may optionally be substituted with hydroxy,
- 25 or a compound of formula




- 35 a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein

-a<sup>1</sup>=a<sup>2</sup>-a<sup>3</sup>=a<sup>4</sup>- represents a bivalent radical of formula

- CH=CH-CH=CH- (a-1);
- N=CH-CH=CH- (a-2);
- N=CH-N=CH- (a-3);
- 40 -N=CH-CH=N- (a-4);
- N=N-CH=CH- (a-5);

- n is 0, 1, 2, 3 or 4; and in case -a<sup>1</sup>=a<sup>2</sup>-a<sup>3</sup>=a<sup>4</sup>- is (a-1), then n may also be 5;
- 45 R<sup>1</sup> is hydrogen, aryl, formyl, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxycarbonyl, C<sub>1-6</sub>alkyl substituted with formyl, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyloxycarbonyl; and

each  $R^2$  independently is hydroxy, halo,  $C_{1-6}$ alkyl optionally substituted with cyano or  $-C(=O)R^4$ ,  $C_{3-7}$ cycloalkyl,  $C_{2-6}$ alkenyl optionally substituted with one or more halogen atoms or cyano,  $C_{2-6}$ alkynyl optionally substituted with one or more halogen atoms or cyano,  $C_{1-6}$ alkyloxy,  $C_{1-6}$ alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di( $C_{1-6}$ alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio,  $-S(=O)_pR^4$ ,  $-NH-S(=O)_pR^4$ ,  $-C(=O)R^4$ ,  $-NHC(=O)H$ ,  $-C(=O)NHNH_2$ ,  $-NHC(=O)R^4$ ,  $-C(=NH)R^4$  or a radical of formula




(c)

- wherein each A independently is N, CH or  $CR^4$ ;  
 B is NH, O, S or  $NR^4$ ;  
 p is 1 or 2; and  
 $R^4$  is methyl, amino, mono- or dimethylamino or polyhalomethyl;
- L is  $C_{4-10}$ alkyl,  $C_{2-10}$ alkenyl,  $C_{2-10}$ alkynyl,  $C_{3-7}$ cycloalkyl, whereby each of said aliphatic group may be substituted with one or two substituents independently selected from
- \*  $C_{3-7}$ cycloalkyl,
  - \* indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo,  $C_{1-6}$ alkyl, hydroxy,  $C_{1-6}$ alkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and  $C_{1-6}$ alkyl-carbonyl,
  - \* phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in  $R^2$ ; or
- L is  $-X-R^3$  wherein
- $R^3$  is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with two, three, four or five substituents each independently selected from the substituents defined in  $R^2$ ; and
- X is  $-NR^1-$ ,  $-NH-NH-$ ,  $-N=N-$ ,  $-O-$ ,  $-C(=O)-$ ,  $-CHOH-$ ,  $-S-$ ,  $-S(=O)-$  or  $-S(=O)_2-$ ;

aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo,  $C_{1-6}$ alkyl,  $C_{3-7}$ cycloalkyl,  $C_{1-6}$ alkyloxy, cyano, nitro, polyhalo $C_{1-6}$ alkyl and polyhalo $C_{1-6}$ alkyloxy,

or a compound of formula



(IV)

the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein

R<sup>1</sup> and R<sup>2</sup> are each independently selected from hydrogen;

hydroxy; amino; C<sub>1-6</sub>alkyl; C<sub>1-6</sub>alkyloxy; C<sub>1-6</sub>alkylcarbonyl; C<sub>1-6</sub>alkyloxy carbonyl; Ar<sup>1</sup>; mono- or di(C<sub>1-6</sub>alkyl)amino; mono- or di(C<sub>1-6</sub>alkyl)aminocarbonyl; dihydro-2(3H)-furanone; C<sub>1-6</sub>alkyl substituted with one or two substituents each independently selected from amino, imino, aminocarbonyl, aminocarbonylamino, hydroxy, hydroxyC<sub>1-6</sub>alkyloxy, carboxyl, mono- or di(C<sub>1-6</sub>alkyl)amino, C<sub>1-6</sub>alkyloxy carbonyl and thienyl; or

R<sup>1</sup> and R<sup>2</sup> taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C<sub>1-6</sub>alkyl)aminoC<sub>1-4</sub>alkylidene;

R<sup>3</sup> is hydrogen, Ar<sup>1</sup>, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy carbonyl, C<sub>1-6</sub>alkyl substituted with C<sub>1-6</sub>alkyloxy carbonyl; and

R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are each independently selected from hydrogen, hydroxy, halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy ;

L is C<sub>1-10</sub>alkyl; C<sub>3-10</sub>alkenyl; C<sub>3-10</sub>alkynyl; C<sub>3-7</sub>cycloalkyl; or

L is C<sub>1-10</sub>alkyl substituted with one or two substituents independently selected from C<sub>3-7</sub>cycloalkyl; indolyl or indolyl substituted with one, two, three or four substituents each independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy, C<sub>1-6</sub>alkylcarbonyl; phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy, C<sub>1-6</sub>alkylcarbonyl; and,


## 23

Ar<sup>1</sup> is phenyl, or phenyl substituted with one, two or three substituents each independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, nitro or trifluoromethyl; with the proviso that compounds (a) to (o)

Co. No.	Alk	R <sup>1</sup> /R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	R <sup>8</sup>
a	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	CH <sub>3</sub>	H	H	H	H
b	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	H	H	NO <sub>2</sub>	H	H
c	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	C <sub>6</sub> H <sub>5</sub>	H	H	H	H	H
d	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	NO <sub>2</sub>	H	CH <sub>3</sub>	H	H
e	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	H	H	NH <sub>2</sub>	H	H
f	4-(2-methylpropyl)phenylmethyl	H/H	H	H	CF <sub>3</sub>	H	H	H
g	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	H	H	Cl	H	H
h	4-(2-methylpropyl)phenylmethyl	H/H	H	H	H	H	H	H
i	3,4-dimethoxyphenylmethyl	H/H	H	H	H	H	H	H
j	2,3-dimethoxyphenylmethyl	H/H	H	H	H	H	H	H
k	3,4-diethoxyphenylmethyl	H/H	H	H	H	H	H	H
l	2-(3,5-(1,1-dimethylethyl)-4-hydroxy-phenyl)ethyl	H/H	H	H	H	H	H	H
m	2-(3,5-(1,1-dimethylethyl)-4-hydroxy-phenyl)ethyl	H/H	H	H	t-Bu	OH	t-Bu	H
n	Phenylmethyl	H/H	H	CH <sub>3</sub>	H	H	H	H
o	Phenylmethyl	H/H	H	H	H	H	H	H

are not included,

or a compound of formula



the N-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein

n is zero, 1, 2 or 3;


X is N or CH;

each R<sup>1</sup> independently is halo, nitro, cyano, amino, hydroxy, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy or trifluoromethyl;

R<sup>2</sup> is hydrogen; C<sub>3-7</sub>alkenyl; C<sub>3-7</sub>alkynyl, aryl; C<sub>3-7</sub>cycloalkyl; C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkyl substituted with hydroxy, C<sub>1-4</sub>alkyloxy, C<sub>3-7</sub>cycloalkyl or aryl;


$R^3$  and  $R^4$  each independently are hydrogen,  $C_{1-6}$ alkyl,  $C_{3-7}$ cycloalkyl or aryl; or  
 $R^3$  and  $R^4$  taken together form a bivalent radical  $-R^3-R^4-$  of formula:

5




wherein  $R^{5a}$ ,  $R^{5b}$ ,  $R^{5c}$ ,  $R^{5d}$  each independently are hydrogen,  $C_{1-6}$ alkyl or aryl; and  
 15 aryl is phenyl or phenyl substituted with one, two or three substituents selected from halo, nitro, cyano, amino, hydroxy,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkyloxy or trifluoromethyl,  
 or a compound of formula

20



30 the *N*-oxides, the stereochemically isomeric forms thereof, and the pharmaceutically acceptable acid addition salts, wherein A and B taken together form a bivalent radical of formula :



40 in the bivalent radicals of formula (a) and (b) the hydrogen atom may be replaced by  $C_{1-6}$ alkyl; in the bivalent radicals of formula (c), (d), (e), (f), one or two hydrogen atoms may be replaced by  $C_{1-6}$ alkyl;

$R^1$  is hydrogen,  $C_{1-6}$ alkyl or halo;

45  $R^2$  is hydrogen or halo;

$R^3$  is hydrogen;  $C_{1-8}$ alkyl;  $C_{3-6}$ cycloalkyl; or  $C_{1-8}$ alkyl substituted with hydroxy, oxo,  $C_{3-6}$ cycloalkyl or aryl;



- Het is a heterocycle selected from the group consisting of pyridine; pyridine substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino or aryl; pyrimidine; pyrimidine substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)-amino or aryl; tetrazole; tetrazole substituted with C<sub>1-6</sub>alkyl or aryl; triazole; triazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)-amino; thiadiazole; thiadiazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)-amino; oxadiazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino; imidazole; imidazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino; thiazole; thiazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino; oxazole; oxazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino; aryl is phenyl or phenyl substituted with C<sub>1-6</sub>alkyl or halo, and the heterocyclic radical "Het" is bound to the sulfur atom via a carbon atom,
- as a solid dispersion in a polymeric matrix, wherein the polymeric matrix is consisting of a homo- or copolymer of N-vinylpyrrolidone.
2. Particles according to claim 1, wherein the copolymer of N-vinylpyrrolidone is a copolymer with vinyl acetate.
  3. Particles according to claim 1 or 2, further comprising a surfactant.
  4. Particles according to claim 3, wherein the surfactant is a PEG-n-hydrogenated castor oil.
  5. Particles according to any of the claims 1 to 3, wherein the surfactant is a low molecular weight polyoxyethylene polyoxypropylene block copolymer.

6. Particles according to any of the claims 1 to 3, further comprising citric acid in amounts of up to 5 % b.w.
7. Particles according to any of the claims 1 to 6, wherein the  
5 homo- or copolymer of N-vinylpyrrolidone is used in amounts of from 40 to 70 % b.w. of the total weight of the dosage form.
8. Particles according to claim 7, wherein the homo- or copoly-  
10 mer of N-vinylpyrrolidone is used in amounts of from 50 to 65 % b.w..
9. Particles according to any of the claims 1 to 8, wherein the controlled release is an instant release of the drug.
- 15 10. Particles according to any of the claims 1 to 8, wherein the controlled release is a sustained release.
11. Particles according to claim 10, further comprising hydroxy-  
20 propyl methyl cellulose in amounts of from 5 to 10 % b.w..
12. Particles according to any of the claims 1 to 11, obtained by forming a homogeneous mixture of the components in the form of a melt, extruding said mixture and shaping of the extru-  
25 date.
13. Particles according to any of the claims 1 to 11, comprising a compound selected from the group consisting of  
4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]-  
benzonitrile;  
30 4-[[2-[(cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-  
benzonitrile;  
4-[[4-amino-5-chloro-6-[(2,4,6-trimethylphenyl)amino]-2-  
pyrimidinyl]-amino]benzonitrile;  
4-[[5-chloro-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]-  
35 amino]benzonitrile;  
4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-  
amino]benzonitrile;  
4-[[4-amino-5-chloro-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-  
pyrimidinyl]amino]benzonitrile;  
40 4-[[5-bromo-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-  
pyrimidinyl]-  
amino]benzonitrile;  
4-[[4-amino-5-chloro-6-(4-cyano-2,6-dimethylphenoxy)-2-  
pyrimidinyl]amino]benzonitrile;  
45 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-  
pyrimidinyl]amino]benzonitrile;

## 27

- 4-[[4-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazin-2-yl]-amino]benzonitrile;
- 4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-1,3,5-triazin-2-yl]amino]benzonitrile;
- 5 4-[[4-[(2,6-dichlorophenyl)methyl]-6-(hydroxyamino)-1,3,5-triazin-2-yl]amino]benzonitrile;
- 1-[[4-[[4-[[4-[(2,4-difluorophenyl)-4-(1H-1,2,4-triazol-1-yl-methyl)-1,3-dioxolan-2-yl]methoxy]phenyl]-1-piperazinyl]-phenyl]-3-(1-methylethyl)-2-imidazolidinone;
- 10 (-)-[2S-[2alpha,4alpha(S\*)]]-4-[[4-[[4-[[2-(4-chlorophenyl)-2-[[[(4-methyl-4H-1,2,4-triazol-3-yl)thio]methyl]-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methyl-propyl)-3H-1,2,4-triazol-3-one,
- 15 a N-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof.
14. Pharmaceutical dosage form, comprising particles according to any of the preceding claims.
- 20 15. Pharmaceutical dosage forms according to claim 13, further comprising one or more pharmaceutically acceptable excipients.

25

30

35

40

45



(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number  
**WO 01/23362 A3**

(51) International Patent Classification<sup>7</sup>: C07D 239/48,  
251/18, 239/50, 403/12, 521/00, 405/14, A61K 31/505,  
A61P 35/00, A61K 9/16, 9/14

(74) Agent: KINZEBACH, Werner; Ludwigsplatz 4, 67059  
Ludwigshafen (DE).

(21) International Application Number: PCT/EP00/09149

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date:  
19 September 2000 (19.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
199 45 982.7 24 September 1999 (24.09.1999) DE

(84) Designated States (*regional*): European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE).

(71) Applicant (*for all designated States except US*): KNOLL  
AKTIENGESELLSCHAFT [DE/DE]; 67061 Lud-  
wigshafen (DE).

Published:  
— with international search report


(72) Inventors; and

(75) Inventors/Applicants (*for US only*): HANTKE, Thomas  
[DE/DE]; Landauerstrasse 5, 67067 Ludwigshafen (DE).  
REHBOCK, Bettina [DE/DE]; Wasgauring 28, 67125  
Dannstadt (DE). ROSENBERG, Jörg [DE/DE]; Bruch-  
strasse 29, 67158 Ellerstadt (DE). BREITENBACH, Jörg  
[DE/DE]; Hans-Sachs-Ring 95A, 68199 Mannheim (DE).

(88) Date of publication of the international search report:  
6 December 2001

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: RATE-CONTROLLED PARTICLES



(I)

(57) Abstract: Rate-controlled particles, comprising  
compounds of formula (I) as a solid dispersion.

WO 01/23362 A3



# INTERNATIONAL SEARCH REPORT

Internat / Application No

PCT/EP 00/09149

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D239/48 C07D251/18 C07D239/50 C07D403/12 C07D521/00  
C07D405/14 A61K31/505 A61P35/00 A61K9/16 A61K9/14

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 872 233 A (JANSSEN) 21 October 1998 (1998-10-21)  page 1 -page 11 ---	1-5, 10-12, 14, 15
Y	EP 0 834 507 A (JANSSEN) 8 April 1998 (1998-04-08) cited in the application page 1 -page 5; claims; tables 2-5 ---	1-5, 10-12, 14, 15
Y	WO 99 02523 A (JANSSEN) 21 January 1999 (1999-01-21) cited in the application the whole document ---  -/--	1-5, 10-12, 14, 15



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

17 May 2001

Date of mailing of the international search report

31/05/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Francois, J

# INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/EP 00/09149

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 13499 A (JANSSEN) 9 May 1996 (1996-05-09) cited in the application page 0; claims; tables 10,11 ----	1-5, 10-12, 14,15
Y	US 5 880 130 A (ANDREW PETER THOMAS) 9 March 1999 (1999-03-09)  column 37, line 10 -column 50 ----	1-5, 10-12, 14,15
Y	WO 97 19065 A (CELLTECH) 29 May 1997 (1997-05-29)  page 1 -page 15; claims ----	1-5, 10-12, 14,15
Y	WO 98 41512 A (CELLTECH) 24 September 1998 (1998-09-24)  page 1 -page 18; claims ----	1-5, 10-12, 14,15
Y	WO 91 18887 A (SMITH-KLINE) 12 December 1991 (1991-12-12)  page 1 -page 10; claims ----	1-5, 10-12, 14,15
P,Y	WO 99 50256 A (JANSSEN) 7 October 1999 (1999-10-07)  the whole document ----	1-5, 10-12, 14,15
P,Y	WO 00 27828 A (JANSSEN) 18 May 2000 (2000-05-18) cited in the application page 15; claims ----	1-5, 10-12, 14,15
P,Y	EP 0 945 443 A (JANSSEN) 29 September 1999 (1999-09-29)  the whole document -----	1-5, 10-12, 14,15



# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No

PCT/EP 00/09149

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 872233	A	21-10-1998	NONE	
EP 834507	A	08-04-1998	AU 3926697 A	09-04-1998
			BR 9704937 A	06-06-2000
			CA 2216486 A	01-04-1998
			CN 1180698 A	06-05-1998
			CZ 9702993 A	11-11-1998
			HR 970526 A	31-10-1998
			HU 9701596 A	28-06-1999
			JP 10114759 A	06-05-1998
			NO 974368 A	02-04-1998
			PL 322369 A	14-04-1998
			SG 53075 A	28-09-1998
			SK 131997 A	11-06-1999
			TR 9701070 A	21-04-1998
			TW 411335 B	11-11-2000
			ZA 9708766 A	30-03-1999
WO 9902523	A	21-01-1999	AU 8857598 A	08-02-1999
			AU 8857698 A	08-02-1999
			BG 103934 A	30-11-2000
			BR 9811676 A	19-09-2000
			BR 9811679 A	19-09-2000
			CN 1262675 T	09-08-2000
			CN 1262684 T	09-08-2000
			WO 9902496 A	21-01-1999
			EP 1000029 A	17-05-2000
			EP 1068200 A	17-01-2001
			HR 20000004 A	31-12-2000
			HR 20000007 A	31-12-2000
			HU 0003078 A	29-01-2001
			JP 2000515560 T	21-11-2000
			NO 20000093 A	10-03-2000
			PL 337648 A	28-08-2000
			SK 182999 A	14-08-2000
			SK 184199 A	11-07-2000
			TR 200000020 T	21-09-2000
WO 9613499	A	09-05-1996	AP 779 A	03-11-1999
			AT 198889 T	15-02-2001
			AU 697744 B	15-10-1998
			AU 3868095 A	23-05-1996
			BG 101402 A	31-10-1997
			BR 9509436 A	06-01-1998
			CZ 9701198 A	18-03-1998
			DE 6951995 D	01-03-2001
			EP 0788496 A	13-08-1997
			FI 971784 A	25-04-1997
			HR 950532 A	31-08-1997
			HU 77360 A	30-03-1998
			IL 115771 A	29-02-2000
			JP 3025907 B	27-03-2000
			JP 9511759 T	25-11-1997
			KR 227231 B	01-11-1999
			NO 971895 A	24-04-1997
			NZ 295353 A	26-08-1998
			PL 319905 A	01-09-1997
			RU 2144032 C	10-01-2000

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/09149

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9613499 A		SK 50797 A	08-04-1998
		TR 960337 A	21-06-1996
		US 5521186 A	28-05-1996
		US 5929075 A	27-07-1999
		ZA 9509084 A	29-04-1997
US 5880130 A	09-03-1999	AU 1194895 A	27-06-1995
		EP 0733045 A	25-09-1996
		WO 9515952 A	15-06-1995
		JP 9506363 T	24-06-1997
		ZA 9409546 A	23-06-1995
WO 9719065 A	29-05-1997	AU 7631496 A	11-06-1997
		EP 0862560 A	09-09-1998
		US 5958935 A	28-09-1999
WO 9841512 A	24-09-1998	AU 6411698 A	12-10-1998
		EP 0970056 A	12-01-2000
		US 6048866 A	11-04-2000
WO 9118887 A	12-12-1991	AU 7971691 A	31-12-1991
WO 9950256 A	07-10-1999	AU 3599799 A	18-10-1999
		BR 9909197 A	05-12-2000
		EP 1066269 A	10-01-2001
		NO 20004809 A	24-11-2000
		TR 200002761 T	22-01-2001
		US 6150360 A	21-11-2000
		EP 0945447 A	29-09-1999
WO 0027828 A	18-05-2000	AU 1046200 A	29-05-2000
		WO 0122938 A	05-04-2001
EP 945443 A	29-09-1999	AU 3599699 A	18-10-1999
		BR 9909191 A	05-12-2000
		WO 9950250 A	07-10-1999
		NO 20004810 A	26-09-2000
		TR 200002760 T	21-12-2000
		US 6197779 B	06-03-2001
		EP 0945442 A	29-09-1999